Rockwell Medical Technologies (RMTI) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
Rockwell Medical Reports Second Quarter Results
August 8, 2016 4:01 PM EDTWIXOM, Mich., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the second quarter of 2016.
Q2 2016 Financial Highlights
Sales were $13.5 million, or 3.8% higher than Q2 2015.Gross profit was $1.5 million compared to $2.1 million in Q2 2015, due to a $0.5 million increase... More
